Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.
- DOI
- 10.1007/s11255-026-05028-0
- Published
- 2026 Sep
- Container
- International urology and nephrology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11255-026-05028-0,
title = {Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.},
author = {Checa-Ros A and Okojie OJ and Steib N and Bellasi A and Salvador-Martínez P and Fortea I and D'Marco L},
year = {2026},
journal = {International urology and nephrology},
doi = {10.1007/s11255-026-05028-0},
url = {https://doi.org/10.1007/s11255-026-05028-0}
}RIS
TY - JOUR TI - Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients. AU - Checa-Ros A AU - Okojie OJ AU - Steib N AU - Bellasi A AU - Salvador-Martínez P AU - Fortea I AU - D'Marco L PY - 2026 JO - International urology and nephrology DO - 10.1007/s11255-026-05028-0 UR - https://doi.org/10.1007/s11255-026-05028-0 ER -
APA
A, C., OJ, O., N, S., A, B., P, S., I, F., & L, D. (2026). Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.. International urology and nephrology. https://doi.org/10.1007/s11255-026-05028-0
Source records
- pubmed · retrieved 2026-09-26T19:13:32.734Z